. Author manuscript; available in PMC: 2021 Jun 1.

Published in final edited form as: Aliment Pharmacol Ther. 2020 May 5;51(12):1222–1232. doi: 10.1111/apt.15770

Table 2.

Helicobacter pylori meta-analyses and risk of inflammatory bowel disease.

Study	Study population	Number of IBD diagnoses	Risk Assessment (95% CI)
Luther, 2010²⁴	Pooled, 5903	1108 (UC)	UC: RR 0.75 (0.62–0.90)
Luther, 2010²⁴	Pooled, 5903	1654 (CD)	CD: RR 0.60 (0.49–0.72)
Wu, 2015²³	Pooled, 3116	548 (UC)	UC: RR 0.55 (0.48–0.64)
Wu, 2015²³	Pooled, 3116	751 (CD)	CD: RR 0.43 (0.37–0.50)
Rokkas, 2015²⁵	Pooled, 9163	1874 (UC)	UC: RR 0.53 (0.42–0.67)
Rokkas, 2015²⁵	Pooled, 9163	2526 (CD)	CD: RR 0.38 (0.31–0.47)
Castaño-Rodríguez, 2017¹³	Pooled, 80,789	2520 (UC)	UC: OR 0.53 (0.44 to 0.65)
		2938 (CD)	CD: OR 0.38 (0.31 to 0.47)
		386 (IBDU)	IBDU: OR 0.43 (0.23 to 0.80)
Tepler, 2019²²	Pooled, 1748	272 (UC)	CagA seropositive
		688 (CD)	UC: OR 0.68 (0.35–1.32)
			CD: OR 0.25 (0.17–0.38)
			CagA seronegative
			UC: OR 0.97 (0.76–1.24)
			CD: OR 0.97 (0.82–1.14)
Piovani, 2019²⁶	Pooled, 83,798	6284 (UC)	UC: OR 0.53 (0.44–0.65)
Piovani, 2019²⁶	Pooled, 83,798	7869 (CD)	CD: OR 0.38 (0.31–0.47)

IBD: Inflammatory bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; IBD-U: Inflammatory bowel disease- Unclassified; OR: odds ratio; RR: relative risk; CI: confidence interval; CagA: cytotoxin-associated gene A